Combinations ; - see below
| Brand Name | Manufacturer Name | Distributor | Drug Strength | Packaging | Formulation | Formulation Strength | Price |
|---|---|---|---|---|---|---|---|
| Glurenor | Menarini Pharmaceuticals | Phillips Pharmaceuticals Ltd. | 30mg | 40 | Tablet | per tablet | KES 568.00 |
| Gliquidone More info | |
|---|---|
| Mode Of Action | Sulphonylurea -antidiabetics like chlorpropamide act mainly by directly stimulating the release of insulin from functioning beta cells of pancreatic islet tissue. To achieve this, they inhibit the ATP-potassium channels on the beta cell membrane and potassium efflux. This results in depolarization and calcium influx, calcium-calmodulin binding, kinase activation, and release of insulin-containing granules by exocytosis. |
| Drug Indication | Uncomplicated and non-ketonic diabetes mellitus (maturity onset type II diabetes). |
| Precautions | Maintain regular medical monitoring; elderly; barbiturate therapy; and dietetic therapy in obese; Addisons disease; and disulfiram-like reaction. |
| Contra-Indications | Diabetes complicated by keto-acidosis; coma; Raynaudss disease; pregnancy; gangrene; severe trauma; fever; severe renal/hepatic/thyroid function impairment; juvenile diabetes mellitus; severe and unstable diabetes; severe inflammation. |
| Side Effects | GI disturbances; blood dyscrasia; hypoglycaemia; jaundice; skin rashes; hypersensitivity reactions; headache; dizziness; oedema; hyponatraemia; paraesthesia; and photosensitivity. |
| Dosage | Initially 15mg daily. (max single dose 60mg, max. daily dose 180mg) |
| Pregnancy Category | Category C |
| Pregnancy Category Description | Drugs which, owing to their pharmacological effects, or may be suspected of causing detrimental effects on human foetus or neonates without causing malfunctions. These effects may be reversible |
| Drug Category | DRUGS AFFECTING NUTRITION AND METABOLISM |
| Drug Sub-Category | Sulphonylureas |